Immune-mediated neuropathies.
Identification of immune-mediated neuropathies is important as these disorders often respond to treatment. Patterns of binding of serum M (monoclonal) proteins and autoantibodies correlate with, and may be diagnostic markers for, specific polyneuropathy syndromes. There is evidence that some of these antibodies may play a pathogenic role in polyneuropathy syndromes. Identification of specific immune polyneuropathy syndromes provides guidance regarding immunosuppressive regimens that may be effective treatments.
Kornberg
A J
AJ
Washington University School of Medicine, Department of Neurology, St. Louis, MO 63110.
Pestronk
A
A
D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D001369:Axons / Q000276:immunology; D003711:Demyelinating Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016472:Motor Neuron Disease / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D009185:Myelin Proteins / Q000276:immunology; D009186:Myelin Sheath / Q000276:immunology; D009468:Neuromuscular Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology*; D009474:Neurons / Q000276:immunology; D011115:Polyneuropathies / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D011129:Polyradiculoneuropathy / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology
D001323:Autoantibodies; D007166:Immunosuppressive Agents; D009185:Myelin Proteins